BlueRidge Life Sciences ("BlueRidge"), a leading life sciences consulting and services platform and a portfolio company of Renovus Capital Partners, today announced the acquisition of Design Science, ...

Mahoney brings deep market expertise to guide biotech and pharmaceutical occupiers BOSTON, MA / ACCESS Newswire / ...

Trinity Life Sciences, the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new ...

BOSTON, June 24, 2025 /PRNewswire/ -- Calibre One, a leading global executive search firm specializing in building world-class leadership teams, is pleased to announce the appointment of Jed Donnelly ...

CHAPEL-EN-LE-FRITH, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences (CLS), a leading integrated drug discovery, development, and manufacturing organisation backed by Limerston ...

BlueRidge Life Sciences, a portfolio company of Renovus Capital Partners, has acquired Design Science, a Philadelphia-based human factors and usability engineering consultancy. No financial terms were ...

The collaboration seeks to address this gap by transitioning organisations from limited experimentation to enterprise-wide impact with generative AI.

Former in-house counsel Andriana Shultz Daly has returned to the firm with client-side insight and courtroom skills to build the firm’s life sciences practice A returning partner to McGuireWoods said ...

Sheppard Mullin's life sciences expertise helped the firm hire a trio of partners with significant knowledge of the industry. Sheppard Mullin announced this week that it has expanded its intellectual ...

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in advisory, insights and analytics for the life sciences industry, has been named to Forbes’ Best Management Consulting Firms of 2025 ...

Attend or sponsor our commercial real estate event in San Diego: Southern California Life Sciences & Biotech Summit.

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .